Open AccessCelecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis
Author(s) -
Peiying Yang,
Xiangsheng Zuo,
Shailesh Advani,
Bo Wei,
Jessica Malek,
R. Sue Day,
Imad Shureiqi
Publication year - 2021
Publication title -
cancer prevention research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.283
H-Index - 91
eISSN - 1940-6207
pISSN - 1940-6215
DOI - 10.1158/1940-6207.capr-21-0066
Subject(s) - celecoxib , familial adenomatous polyposis , medicine , colorectal cancer , bioavailability , gastroenterology , colonoscopy , cancer , pharmacology
Why celecoxib exerts chemopreventive activity in only some familial adenomatous polyposis (FAP) patients remains poorly understood. We conducted a phase II clinical study to identify potential predictive biomarkers for celecoxib chemopreventive activity in FAP. Twenty-seven patients with FAP completed a 6-month oral course of 400 mg of celecoxib twice a day; they underwent colonoscopies before and after celecoxib treatment to assess colorectal polyp tumor burden and to obtain normal and polyp colorectal biopsies to measure celecoxib, 13-S-hydroxyoctadecadienoic acid (13-HODE), 15-HETE, 12-HETE, and LTB4 levels by LC/MS-MS. Celecoxib levels in sera from those patients were also measured before treatment and after 2, 4, and 6 months of treatment. Nineteen of the 27 patients experienced a response to celecoxib, with a ≥ 28% reduction of colonic polyp burden on the basis of a reproducible quantitative assessment of colonoscopy results. Celecoxib levels were significantly lower in polyp tissues than in normal colorectal tissues. Celecoxib levels in sera and normal colorectal tissues were correlated in patients who experienced a response to celecoxib but not in those who did not. Among the measured lipoxygenase products, only 13-HODE levels were significantly lower in polyp tissues than in normal tissues. Our findings demonstrate the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical response in patients with FAP.